RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Clinical trials for RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) explained in plain language.
Never miss a new study
Get alerted when new RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) trials appear
Sign up with your email to follow new studies for RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Tracking a new lymphoma Drug's Real-World performance
Disease control OngoingThis study is observing how well the drug epcoritamab works for patients with an aggressive type of lymphoma (DLBCL) that has returned or stopped responding to other treatments. It follows 150 patients in Italy who are already receiving the drug through a special access program, …
Matched conditions: RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Sponsor: Andrés José Maria Ferreri • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Higher stem cell dose may boost immune recovery after lymphoma treatment
Disease control OngoingThis study investigates whether giving a higher dose of a patient's own stem cells during transplant leads to better immune system recovery and outcomes for people with aggressive lymphoma that has returned or resisted treatment. Participants with relapsed or refractory diffuse l…
Matched conditions: RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC